Compare Crowdstrike Holdings Inc (CRWD) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crowdstrike Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Crowdstrike Holdings Inc trades at $275.04 (market cap $269.31B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Crowdstrike Holdings Inc is far larger — about 2.1× Vertex Pharmaceuticals Incorporated's market cap, and Crowdstrike Holdings Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crowdstrike Holdings Inc for 97 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| CRWD | VRTX | |
|---|---|---|
Market Cap | $269.31B | $127.55B |
Volume | 9,381,560 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $278.86 | $557.96 |
52-Week Low | $87.56 | $407.37 |
Typical Hold Time | 97 Days | 120 Days |
Enterprise Value | $265.11B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CrowdStrike (CRWD) trades at $263.01, down 0.92% today but near its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Revenue growth remains robust at $3.95B for 2025, though profitability is challenged with a net margin of -0.49%. Analyst sentiment is overwhelmingly positive with 76% buy ratings and a $239.38 consensus target, while recent news highlights AI-driven cybersecurity demand as a key growth catalyst.
Outlook remains favorable given CrowdStrike's leadership in AI-native cybersecurity and expanding market opportunities. However, elevated valuation multiples (P/S 49.86) and competitive pressures present risks. The stock's proximity to all-time highs suggests near-term consolidation potential, but long-term growth prospects in cybersecurity remain compelling.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
